Visceral hyperalgesia refers to increased pain sensation in response to gastrointestinal sensory stimulus.^[@bibr1-2329048X17693123][@bibr2-2329048X17693123]-[@bibr3-2329048X17693123]^ In neonates with neurological impairments, visceral hyperalgesia has been described as an underlying source of neuropathic pain that manifests as irritability, hypertonicity, poor weight gain, and feeding intolerance, all common neurological and gastrointestinal symptoms of prematurity.^[@bibr2-2329048X17693123][@bibr3-2329048X17693123][@bibr4-2329048X17693123][@bibr5-2329048X17693123]-[@bibr6-2329048X17693123]^ Visceral hyperalgesia is often misdiagnosed or not even considered as an etiology.^[@bibr7-2329048X17693123]^ There are only a few case reports and case series that describe visceral hyperalgesia in neonates and its causes, diagnosis, and treatment options.^[@bibr1-2329048X17693123][@bibr2-2329048X17693123][@bibr3-2329048X17693123][@bibr4-2329048X17693123][@bibr5-2329048X17693123]-[@bibr6-2329048X17693123]^ These same case reports describe the successful use of gabapentin as a treatment for visceral hyperalgesia in neonates. The mechanism of action of gabapentin, a γ-aminobutyric acid analog, is thought to inhibit pain via voltage-dependent calcium ion channels in the central nervous system and relieve the neuropathic pain in response to the gastrointestinal stimulus.^[@bibr7-2329048X17693123][@bibr8-2329048X17693123][@bibr9-2329048X17693123]-[@bibr10-2329048X17693123]^

In this case report, the authors present a preterm infant with a myelomeningocele treated with gabapentin for visceral hyperalgesia that manifested with irritability, hypertonicity, poor weight gain, and feeding intolerance. The authors also provide a review of the available literature of gabapentin use in neonates and offer specific recommendations on when to consider visceral hyperalgesia and start gabapentin in neonates with neurological impairment and chronic unexplained gastrointestinal manifestations. The institutional review board at Atlantic Health System approved the study.

Case Report {#section1-2329048X17693123}
===========

Our patient is a male infant born via cesarean section at 29 weeks' gestational age to a 24-year-old mother for worsening preeclampsia. The infant's birth weight was 995 g (20th percentile) and head circumference was 25 cm (10th percentile). The initial physical examination revealed a 1 cm × 1 cm neural tube defect in the lumbosacral area consistent with a myelomeningocele that was not detected prenatally. He underwent primary closure of the defect at 1 week of life. The initial and subsequent head ultrasounds did not identify hydrocephalous, intraventricular hemorrhage, or Chiari II malformation. The head circumference grew along the 10th percentile throughout his hospital course. He had normal, symmetric movement of his 4 extremities with increased tone and normal urination and stooling patterns. He had no sensory deficits noted on the dermatomal evaluation of the lower extremities, especially in the sacral region, before or after repair. He passed the auditory brain stem response-hearing screen and had no retinopathy of prematurity.

The infant had poor weight gain (\<15 g/d from birth to day of life 100), extreme irritability, hypertonicity, and significant feeding intolerance (vomiting and arching with feeds) that was out of proportion for prematurity. At 42 weeks postmenstrual age, he was still requiring feedings via a nasogastric tube. The diagnostic workup for his gastrointestinal and neurological manifestations of pain and irritability, including brain and spine magnetic resonance imaging, and modified barium/follow through speech evaluation did not reveal any pathology.

At 43 weeks postmenstrual age, with no identifiable source for the irritability and feeding intolerance, manifested as poor oral intake and lack of weight gain, a diagnosis of visceral hyperalgesia was considered and the infant was trialed on gabapentin. The dose was titrated to effect by administering gabapentin at 5 mg/kg/d by mouth at night on days 1 and 2, 10 mg/kg/d divided twice daily on days 3 and 4, and 15 mg/kg/d divided 3 times daily from day 5 onward. The regimen was adopted from the previous literature, and gabapentin was initially administered via the nasogastric tube.^[@bibr1-2329048X17693123],[@bibr4-2329048X17693123]^ His nasogastric tube was removed after 3 days of starting the medicine, at which time the medicine was switched to oral administration, and he gained an average of 28 g/d until his discharge at 46 weeks postmenstrual age. His tone improved and irritability dissipated. He was discharged home on gabapentin, and the dose and interval were slowly weaned over 3 months by his pediatric neurologist. Adverse clinical events associated with initiation, maintenance, and discontinuation of gabapentin were closely monitored but never experienced by this patient ([Table 1](#table1-2329048X17693123){ref-type="table"}).^[@bibr1-2329048X17693123],[@bibr3-2329048X17693123],[@bibr4-2329048X17693123],[@bibr10-2329048X17693123],[@bibr11-2329048X17693123]^

###### 

Adverse Experiences of Gabapentin Use.

![](10.1177_2329048X17693123-table1)

  Phase                                             Adverse Events
  ------------------------------------------------- -------------------------------------------------------------------------------------------
  Initiation                                        GI intolerance^[@bibr10-2329048X17693123]^
  Oversedation^[@bibr10-2329048X17693123]^          
  Bradycardia^[@bibr3-2329048X17693123]^            
  Maintenance                                       Nystagmus^[@bibr1-2329048X17693123],[@bibr4-2329048X17693123],[@bibr10-2329048X17693123]^
  Somnolence, fatigue^[@bibr10-2329048X17693123]^   
  Ataxia/dizziness^[@bibr10-2329048X17693123]^      
  Nausea/vomiting^[@bibr10-2329048X17693123]^       
  Discontinuation                                   Autonomic instability^[@bibr10-2329048X17693123],[@bibr11-2329048X17693123]^
  Tachycardia^[@bibr3-2329048X17693123]^            
  Emesis                                            
  Agitation^[@bibr3-2329048X17693123]^              

Abbreviation: GI, gastrointestinal.

Discussion {#section2-2329048X17693123}
==========

In this case study, the authors present a neurologically impaired preterm infant with a repaired myelomeningocele who was successfully treated with gabapentin for visceral hyperalgesia. The diagnosis and treatment options for neonates with neurological impairments and persistent irritability due to visceral hyperalgesia are an underreported topic in the literature. The challenge of identifying symptoms of neuropathic pain and distinguishing them from common neonatal morbidities makes the task of adequately treating more difficult. In patients with severe neurologic impairment (ie, intraventricular hemorrhage, periventricular leukomalacia, cystic encephalomalacia, ventriculoperitoneal shunt, myelomeningocele, etc), gastroesophageal reflux, constipation, feeding difficulties and poor weight gain due to poor gut motility, spasticity, and pain have all been described as potential manifestations of visceral hyperalgesia ([Table 2](#table2-2329048X17693123){ref-type="table"}).^[@bibr7-2329048X17693123]^ Often, there is a reliance on nasogastric or gastrostomy tube.^[@bibr3-2329048X17693123],[@bibr4-2329048X17693123],[@bibr6-2329048X17693123]^ These patients may also present with apneic episodes, grimacing, inconsolability, restlessness, hypertonia, stiffening, and back arching.^[@bibr1-2329048X17693123],[@bibr2-2329048X17693123]^ If a thorough investigation has been performed in neonates with coexisting neurological impairments with these complex comorbidities, and no identifiable source has been found, then visceral hyperalgesia should be considered, diagnosed, and properly treated.

###### 

Available Literature That Describes the Use of Gabapentin in Neonates.

![](10.1177_2329048X17693123-table2)

  Study                                                     GA (weeks) and BW (g)   Pertinent Diagnosis                                                                  CNS Morbidities                                                   GI Morbidities                                                    Indications for Starting Gabapentin                                                                 Prior Medications                                                                        Initial Dose                                                                                                                  Discharge Dose                                    Side Effects                                                     Outcome
  --------------------------------------------------------- ----------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Behm and Kearns, 2001^[@bibr6-2329048X17693123]^          36 ^5/7^ and 2475       Amyoplasia congenita Arthrogyroposis Dislocated hips Clubfeet Dysplastic shoulders   NAS Pain and irritability with any movement                       Nasogastric feeding tube                                          Pain with movements                                                                                 Acetaminophen Ibuprofen                                                                  7 mg/kg once daily                                                                                                            10 mg/kg once daily                               None                                                             All bottle feedings Decreased pain with changing diaper Calm, not sedated, accepted pacifier
  Hauer and Mackey, 2013^[@bibr2-2329048X17693123]^         31 and NR               Prematurity Twin--twin transfusion Obstructive apnea                                 Cystic encephalomalacia and cerebral loss Mild spasticity         GER                                                               Pain that was a trigger for:Abnormal breathing patternsEpisodic hypertonia Poor sleeping patterns   Proton pump inhibitor (unspecified)                                                      20 mg/kg/d divided TID (initiated as outpatient at 2 months of life)                                                          Titrated to effect                                NR                                                               Improvement of irritability and sleep Resolution of apnea
  Hauer and Mackey, 2013^[@bibr2-2329048X17693123]^         25 and NR               Extreme prematurity Chronic lung disease Apnea and bradycardia Tracheostomy          Periventricular leukomalacia Episodic irritability                Gastrostomy tube Poor oral feedings                               Pain that was a trigger for:Abnormal breathing patternsEpisodic hypertonia                          Metoclopramide Proton pump inhibitor (unspecified)                                       Initial dose not stated (initiated at 5 months of life)                                                                       22 mg/kg/d divided TID                            None                                                             Decreased cardiorespiratory events Decreased irritability
  Haney et al, 2009^[@bibr4-2329048X17693123]^              39 and NR               Microduplication of chromosome 22q11.2 Pulmonary hypertension LGA                    Decreased alertness Hypotonia and weak grasp                      NEC Functional short gut syndrome Neonatal giant cell hepatitis   Pain and irritability                                                                               Lorazepam Morphine Phenobarbital                                                         5 mg/kg at bedtime                                                                                                            5 mg/kg morning 10 mg/kg lunch 10 mg/kg bedtime   Nystagmus                                                        Improvement in the infant's tone and disposition
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            23 and 670              Extreme prematurity Chronic lung disease Tracheostomy                                Intraventricular hemorrhage Ventriculoperitoneal shunt Seizures   Gastrostomy- jejunostomy tube Feeding intolerance                 Feeding intolerance/seizures                                                                        Levetiracetam                                                                            15 mg/kg/d divided TID                                                                                                        5 mg/kg/d                                         Tachycardia, emesis, and agitation with abrupt discontinuation   Improved feeding tolerance
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            24 and 430              Extreme prematurity Chronic lung disease Tracheostomy                                Intraventricular hemorrhage Ventriculoperitoneal shunt Seizures   Gastrostomy tube                                                  Visceral hyperalgesia/agitation                                                                     Clonidine Diazepam Acetaminophen                                                         20 mg/kg/d divided q12                                                                                                        30 mg/kg/d divided TID                                                                                             Improved feeding tolerance
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            24 and 860              Extreme prematurity Chronic lung disease                                             Hypertonia                                                        Gastrostomy tube GER                                              Visceral hyperalgesia/seizures                                                                      Phenobarbital Diazepam Methadone Morphine Lorazepam                                      10 mg/kg/d divided q12                                                                                                        Died                                                                                                               Decreased irritability and reduced use of benzodiazepines and morphine
  Edwards et al 2015^[@bibr3-2329048X17693123]^             24 and 790              Extreme prematurity Chronic lung disease                                             Hypertonia                                                        Gastrostomy tube GER                                              Visceral hyperalgesia/agitation                                                                     Baclofen                                                                                 10 mg/kg/d divided q12                                                                                                        10 mg/kg/d divided q12                            Tachycardia, emesis, and agitation with abrupt discontinuation   Decreased irritability Improved oral feeding Toleration of gastrostomy feeds
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            26 and 890              Extreme prematurity Chronic lung disease Twin gestation                              Hypertonia                                                        Gastrostomy tube Bowel obstruction                                Visceral hyperalgesia/ agitation                                                                    Baclofen Lorazepam                                                                       10 mg/kg/d divided q12                                                                                                        5 mg/kg/d divided q12                             Bradycardia: resolved with lower dose                            Weaned off benzodiazepines
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            26 and 890              Extreme prematurity Chronic lung disease Twin gestation                              Hypertonia                                                        Gastrostomy tube                                                  Visceral hyperalgesia/agitation                                                                     Baclofen Lorazepam                                                                       10 mg/kg/d divided q12                                                                                                        Not applicable                                    Bradycardia: discontinued without trial of lower dose            
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            27 and 1003             Congenital intestinal atresia Tracheostomy                                           Microcephaly Lissencephaly Seizures                               Gastrostomy-jejunostomy tube                                      Visceral hyperalgesia/agitation                                                                     Diazepam Phenobarbital Topiramate Baclofen Lorazepam                                     5 mg/kg q24                                                                                                                   15 mg/kg/d divided q12                                                                                             Decreased sympathetic hyperactivity Weaned off benzodiazepines
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            32 and 1900             Preterm Pulmonary hypoplasia Tracheostomy                                            Joint contractures                                                Gastrostomy tube                                                  Visceral hyperalgesia/agitation                                                                     Baclofen Clonidine Lorazepam                                                             10 mg/kg/d divided q12                                                                                                        15 mg/kg/d divided TID                            Bradycardia that resolved at lower dose                          Weaned off benzodiazepines and methadone
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            38 and 3500             Full term                                                                            HIE Hypertonia                                                    Gastrostomy tube GER                                              Visceral hyperalgesia/agitation                                                                     Baclofen Lorazepam                                                                       15 mg/kg/d divided q8                                                                                                         15 mg/kg/d divided q12                                                                                             Decreased irritability Improved oral feeding
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            39 and 2940             Full term Congenital diaphragmatic hernia ECMO Tracheostomy                          NAS Seizures                                                      Gastrostomy-jejunostomy tube                                      Visceral hyperalgesia/agitation/seizures                                                            Clonidine Lorazepam Methadone Phenobarbital                                              10 mg/kg/daily divided q12                                                                                                    Not applicable                                                                                                     Decreased irritability Decreased use of benzodiazepines
  Edwards et al, 2015^[@bibr3-2329048X17693123]^            41 and 2921             VATER syndrome Chromosomal abnormality Pulmonary hypoplasia Tracheostomy             NAS Seizures                                                      Gastrostomy tube                                                  Agitation/seizures                                                                                  Clonidine Diazepam Levetiracetam Oxcarbazepine Phenobarbital Dexmedetomidine Midazolam   15 mg/kg/d divided TID                                                                                                        15 mg/kg/d divided TID                                                                                             Decreased irritability
  Brzenski and Greenberg, 2015^[@bibr5-2329048X17693123]^   NR and 3500             Term                                                                                 NAS                                                               Poor weight gain Poor oral feedings                               Extreme irritability and poor sleep                                                                 Morphine Clonidine                                                                       10 mg/kg/d divided TID                                                                                                        20 mg/kg/d divided TID                            None                                                             Decreased irritability Weaned off morphine and clonidine
  This study                                                29 and 995              Premature                                                                            Myelomeningocele                                                  Poor weight gain Poor oral feedings                               Visceral hyperalgesia/agitation                                                                     Acetaminophen                                                                            5 mg/kg once daily for 2 days, increased to 10 mg/kg/d divided Q12 for 2 days, and then increased to 15 mg/kg/d divided TID   15 mg/kg/d divided TID                            None                                                             Improved oral intake \>20 g/d weight gain Improved tone

Abbreviations: BW, birth weight; CNS, central nervous system; ECMO; extracorporeal membrane oxygenation; GA, gestational age; GER, gastroesophageal reflux; GI, gastrointestinal; HIE, hypoxic ischemic encephalopathy; LGA, large for gestational age; NAS, neonatal abstinence syndrome; NEC, necrotizing enterocolitis; NR, not reported; Q, every; TID, 3 times a day; VATER syndrome, vertebral anomalies, anal atresia, tracheoesophageal fistula and/or esophageal atresia, renal and radial anomalies.

Gabapentin has been successfully used as a treatment for visceral hyperalgesia in neonates with gastrointestinal and neurological comorbidities.^[@bibr2-2329048X17693123][@bibr3-2329048X17693123][@bibr4-2329048X17693123][@bibr5-2329048X17693123]-[@bibr6-2329048X17693123]^ This is the 17th case to describe a neonate, preterm (n = 11) or term (n = 5), with neuropathic pain treated with gabapentin. In [Table 2](#table2-2329048X17693123){ref-type="table"}, the authors briefly describe each case by outlining the gestational age of the neonate, the pertinent neurological and gastrointestinal symptoms, the indications for starting gabapentin, initial and maintenance doses, reported side effect profile, and observed outcomes. Although there is a growing literature on the clinical responses and adverse events related to gabapentin use in neonates, both term and preterm,^[@bibr2-2329048X17693123][@bibr3-2329048X17693123][@bibr4-2329048X17693123][@bibr5-2329048X17693123]-[@bibr6-2329048X17693123]^ there are no guidelines or recommendations on when or how to consider gabapentin use in neonates, to initiate and titrate the medication to effect, and to discontinue the medication.

Pharmacokinetics of Gabapentin {#section3-2329048X17693123}
------------------------------

Haig et al^[@bibr8-2329048X17693123]^ and Ouellet^[@bibr9-2329048X17693123]^ found that gabapentin exposure, the apparent total clearance of the drug from plasma after oral administration, in children less than 5 years of age is 30% less than that observed in older children when dosed on a mg/kg basis. Younger children also have a reduced plasma concentration with a starting dose of 10 mg/kg/d.^[@bibr8-2329048X17693123][@bibr9-2329048X17693123]-[@bibr10-2329048X17693123]^ The medication is eliminated via glomerular filtration as unchanged drug, making creatinine clearance the major determinant of oral gabapentin clearance and dosage adjustment necessary in patients with renal impairment.^[@bibr10-2329048X17693123]^ The suggested dose of gabapentin in a safety and efficacy trial in younger children was less than 40 mg/kg/d in 3 divided doses.^[@bibr8-2329048X17693123]^ Gabapentin does not bind significantly to plasma proteins and is not appreciably metabolized. Peak plasma gabapentin concentrations occur 2 to 3 hours after administration of the dose and the elimination half-life averages between 4 and 5 hours. Volume of distribution is linearly related to body weight.^[@bibr8-2329048X17693123],[@bibr9-2329048X17693123]^

The 17 case reports in [Table 2](#table2-2329048X17693123){ref-type="table"} have different initial starting doses and dose intervals that range from 5 mg/kg administered once daily to 20 mg/kg/d divided every 8 hours. In the study by Edwards et al,^[@bibr3-2329048X17693123]^ 6 of 8 preterm infants were started on a regimens of 10 mg/kg/d divided every 12 hours. Three infants experienced bradycardia within the first 24 hours, which resolved with lower doses in 2 of the 3. None of the cases identified gastrointestinal intolerance or oversedation, and 1 case documented nystagmus after 1 month of use, which persisted throughout the remainder of treatment and resolved after discontinuation.^[@bibr4-2329048X17693123]^ Nystagmus was also identified in 1 child in a case series of 9 children aged 3 months to 22 years.^[@bibr1-2329048X17693123]^ In all the case series and reports, the dose and dosing intervals were titrated to effect based on clinical response and tolerability.^[@bibr1-2329048X17693123][@bibr2-2329048X17693123][@bibr3-2329048X17693123][@bibr4-2329048X17693123][@bibr5-2329048X17693123]-[@bibr6-2329048X17693123]^ Once the symptoms were stabilized and no side effects were observed from the medication, the dose was maintained and followed accordingly. Each case report titrated to a dose below the threshold of 40 mg/kg/d divided 3 times a day ([Table 2](#table2-2329048X17693123){ref-type="table"}).^[@bibr8-2329048X17693123]^ In our case study, the initial dose and dosing interval were titrated more conservatively than the published literature allowing for proper monitoring of the side effect profile during the titration window ([Table 2](#table2-2329048X17693123){ref-type="table"}).

Adverse Experiences of Gabapentin Use {#section4-2329048X17693123}
-------------------------------------

The side effects associated with gabapentin use in adults and children are described in [Table 1](#table1-2329048X17693123){ref-type="table"} and can occur during the initiation, maintenance, or discontinuation phase. There is no clear dose escalation to side effect relationship with gabapentin as most adverse experiences occur at lower doses.^[@bibr10-2329048X17693123]^ Upon initiation, side effects may include gastrointestinal intolerance, oversedation, and bradycardia.^[@bibr3-2329048X17693123],[@bibr10-2329048X17693123]^ The sustained use of gabapentin may lead to nystagmus that appears to resolve upon discontinuation.^[@bibr1-2329048X17693123],[@bibr4-2329048X17693123]^ The most common adverse experiences in adult studies are somnolence, fatigue, ataxia, and dizziness.^[@bibr10-2329048X17693123]^ Recently, Edwards et al^[@bibr3-2329048X17693123]^ reported a triad of tachycardia, emesis, and agitation with abrupt cessation of the medication in 2 infants who were made nil per os (NPO) for clinical deterioration ([Table 2](#table2-2329048X17693123){ref-type="table"}). Similar autonomic withdrawal symptoms, such as hyperactivity, irritability, and agitation, have been noted in adults who abruptly discontinue the medication.^[@bibr10-2329048X17693123],[@bibr11-2329048X17693123]^

Dose and Interval Recommendations: Initiation and Titration {#section5-2329048X17693123}
-----------------------------------------------------------

Gabapentin can be chosen as a treatment option for visceral hyperalgesia because of its favorable side effect profile, minimal respiratory depressive effects, and its relative lack of interaction with other medications.^[@bibr3-2329048X17693123],[@bibr7-2329048X17693123]^ The goal is to optimize the dose and interval to relief of symptoms while minimizing adverse effects. Based on previous case reports, the authors recommend a starting dose of 5 to 10 mg/kg administered once daily at bedtime.^[@bibr1-2329048X17693123],[@bibr7-2329048X17693123]^ To effectively titrate, the authors suggest increasing the dose and frequency every 1 to 2 days to a maximum of 40 mg/kg/d divided 3 times daily. If no side effects are reported from initiation of the medication and the visceral hyperalgesia symptoms are not yet stabilized, then the dosage can be titrated up accordingly. Although the upper limit appears to be 40 mg/kg/d,^[@bibr8-2329048X17693123]^ only 1 case report documented a dose greater than 30 mg/kg/d.^[@bibr3-2329048X17693123]^ Schwantes and O'Brien^[@bibr7-2329048X17693123]^ provide a similar advancement protocol in children with a recommended starting dose of 15 mg/kg/d divided 3 times daily up to 45 mg/kg/d. Increases to 60 mg/kg/d may be needed in children, but doses greater than 60 mg/kg/d are not likely to be more effective.^[@bibr7-2329048X17693123]^ Previous studies suggest that the initial dose be started at night, followed by the addition of a morning dose, and eventually an afternoon dose in carefully spaced intervals ([Table 2](#table2-2329048X17693123){ref-type="table"}).^[@bibr1-2329048X17693123],[@bibr7-2329048X17693123]^ The long-term clinical and pharmacological significance of gabapentin use for symptom relief for chronic irritability in neurologically impaired children is currently being explored in a prospective, randomized, double-blind, placebo-controlled, crossover clinical trial.^[@bibr12-2329048X17693123]^

Conclusion {#section6-2329048X17693123}
==========

The diagnosis of visceral hyperalgesia should be strongly considered in neonates with neurological impairment and other coexisting gastrointestinal morbidities that are associated with a neuropathic pain response. These infants with refractory visceral hyperalgesia may benefit from gabapentin administration that should be titrated to effect and monitored closely for side effects. With increased clinical experience and research, gabapentin may prove to offer a well-tolerated and effective therapy for chronic symptoms in infants with visceral hyperalgesia.
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